Pharmacy and Therapeutics Committee Agenda for June 3, 2005
The Pharmacy and Therapeutics Committee will meet Friday, June 3, 2005 from 10:30 a.m. to 3:00 p.m., in meeting room 4, Concourse, Empire State Plaza, Albany, New York
1. Proposal: To prior authorize the oral prescription drugs used to treat erectile dysfunction.
Description: The Committee will consider requiring that all oral erectile dysfunction drugs (phosphodiesterase type 5 inhibitors) be subject to prior authorization in order to address potential overuse or misuse of these drugs.
Therapeutic Class: erectile dysfuntion drugs
List of Drugs Affected: Viagra (sildenafil), Levitra (vardenafil) and Cialis (tadalafil).
2. Proposal: Prior authorization of prescription proton pump inhibitors
Description: The Committee will consider requiring all prescription proton pump inhibitors to be subject to prior authorization in order to assure appropriate utilization of the prescription and non-prescription alternatives within this drug category.
Therapeutic Class: Proton pump inhibitors (drugs used to surpress gastric acid secretion)
List of Drugs Affected: Includes Prilosec (omperazole), Nexium (esomeprazole), Previcid (lansoprazole), Aciphex (rabeprazole), and Protonix (pantoprazole)
10:30 - 10:40 Welcome and Introductions
10:40 - 11:40 Comments from interested parties *
11:40 - 3:00 Committee Discussion
11:40 - 12:30 Development of recommendations for prior authorization of phosphodiesterase type 5 inhibitors
12:30 - 1:00 Lunch Break
1:00 - 2:45 Development of recommendations for prior authorization of proton pump inhibitors
2:45 - 3:00 Summary of recommendations and adjournment
*Speakers must notify DOH at least 48 hrs in advance of their intent to speak at the committee meeting. To get on the agenda, you may call 518-486-3209 or e-mail email@example.com (please reference P&T Committee). Public comments are limited to the items on the agenda and must be brief. Written material may also be submitted to the Committee if received by DOH at least 48 hours in advance of the meeting. Written material should summarize key points and may not exceed two pages in length.